Beacon BreakingNews – Subcutaneous Velcade Receives FDA Approval
Millennium: The Takeda Oncology Company announced today that the U.S Food and Drug Administration has approved subcutaneous administration of Velcade for the treatment of multiple myeloma and relapsed mantle cell lymphoma.
Velcade (bortezomib), which is marketed by Millennium and its parent company Takeda Pharmaceutical Company Limited (TSE:4502), is currently approved to be administered intravenously (infused into a vein).
The FDA decision to approve the subcutaneous administration of Velcade (injection into fat just below the skin, often abbreviated as subcu or subQ) was based on results of a Phase 3 study comparing subcutaneous and intravenous administration of Velcade for myeloma patients.
The results showed that subcutaneous Velcade is as effective as intravenous Velcade, but subcutaneous administration reduces the frequency and seriousness of side effects. In particular, subcutaneous Velcade causes less peripheral neuropathy, pain and tingling in the extremities and a common side effect of Velcade (see related Beacon news).
In addition to being safer, subcutaneous Velcade may be more convenient for many patients. Subcutaneous administration is faster and does not require an accessible vein. Currently, subcutaneous Velcade is being administered in hospitals or clinics by health care professionals, but eventually patients may be able to administer it at home.
Although subcutaneous administration of Velcade was not officially approved by any regulatory agencies until today, some physicians in the United States and several other countries have been administering Velcade subcutaneously since the release of the clinical trial results showing better tolerability (see related Beacon news).
The prescribing information for Velcade will be updated to say that Velcade can be used via intravenous or subcutaneous administration, but not intrathecal administration (injection into the spinal canal). Inadvertent injection into the spinal canal has resulted in death.
For more information about the FDA approval, see the Millennium press release.
Related Articles:
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- Adding Clarithromycin To Velcade-Based Myeloma Treatment Regimen Fails To Increase Efficacy While Markedly Increasing Side Effects
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
This is great news!!!!
Subcutaneous administration of Velcade has now been approved in Canada as well. Here is the first part of the press release announcing the news:
Health Canada approves subcutaneous administration of VELCADE®* in multiple myeloma
Canada NewsWire
TORONTO, March 15, 2012
New route of administration provides greater convenience and choice for physicians and patients
TORONTO, March 15, 2012 /CNW/ - Janssen Inc. announced today that Health Canada has approved an expanded indication for VELCADE® (bortezomib) to include subcutaneous administration in the treatment of multiple myeloma, a form of blood cancer.
- - - -
The new route of administration is reflected in the latest version of the official Velcade product monograph (prescribing information) for Canada. To see the monograph, do a search on the product name "Velcade" by entering "Velcade" as the product name in the "Search by Other Criteria" section on this page:
After you push the "Search" button at the bottom of the page, you'll be taken to a new page that has a link to the up-to-date product monograph.
Wow!! That is great news! I have been wondering about the issue ever since it was it was announced that sub-q was approved in the US. Hopefully that will help some people to avoid the neuropathy issues that plague MM patients.
Get new Myeloma Beacon articles by email.